ATE549355T1 - Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten - Google Patents

Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten

Info

Publication number
ATE549355T1
ATE549355T1 AT04735923T AT04735923T ATE549355T1 AT E549355 T1 ATE549355 T1 AT E549355T1 AT 04735923 T AT04735923 T AT 04735923T AT 04735923 T AT04735923 T AT 04735923T AT E549355 T1 ATE549355 T1 AT E549355T1
Authority
AT
Austria
Prior art keywords
compositions containing
antibody fragments
directed against
toxin
containing large
Prior art date
Application number
AT04735923T
Other languages
English (en)
Inventor
Jane Louise Holley
Carl Nicholas Mayers
David Whitfield
Timothy John Gilby Brooks
Original Assignee
Secr Defence
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Secr Defence filed Critical Secr Defence
Application granted granted Critical
Publication of ATE549355T1 publication Critical patent/ATE549355T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT04735923T 2003-06-03 2004-06-03 Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten ATE549355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0312642.2A GB0312642D0 (en) 2003-06-03 2003-06-03 Pharmaceutical composition
PCT/GB2004/002351 WO2004106376A1 (en) 2003-06-03 2004-06-03 Compositions comprising large and small binding fragments of antibodies against the same toxin

Publications (1)

Publication Number Publication Date
ATE549355T1 true ATE549355T1 (de) 2012-03-15

Family

ID=9959179

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04735923T ATE549355T1 (de) 2003-06-03 2004-06-03 Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten

Country Status (8)

Country Link
US (1) US7618625B2 (de)
EP (1) EP1629009B8 (de)
JP (1) JP5065677B2 (de)
AT (1) ATE549355T1 (de)
AU (1) AU2004242760B2 (de)
DK (1) DK1629009T3 (de)
GB (1) GB0312642D0 (de)
WO (1) WO2004106376A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563874B2 (en) 1998-08-31 2009-07-21 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
EP2153848A3 (de) 2005-01-27 2010-07-21 The Regents of the University of California Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
WO2008041012A1 (en) * 2006-10-06 2008-04-10 The Secretary Of State For Defence Pharmaceutical composition comprising antibodies against a toxin
GB2442466A (en) * 2006-10-06 2008-04-09 Secr Defence Method of producing antibodies against toxins
WO2009008916A2 (en) 2007-03-22 2009-01-15 The Regents Of The University Of Californina Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040384A1 (en) * 2001-11-05 2003-05-15 Board Of Regents, The University Of Texas System Recombinant antibodies for the detection and neutralization of anthrax toxin
US20050042775A1 (en) * 2003-08-21 2005-02-24 Nicholas Pomato Botulinum antitoxin compositions and methods

Also Published As

Publication number Publication date
DK1629009T3 (da) 2012-05-29
US20070036805A1 (en) 2007-02-15
EP1629009B8 (de) 2012-04-18
JP2007527372A (ja) 2007-09-27
GB0312642D0 (en) 2003-07-09
JP5065677B2 (ja) 2012-11-07
US7618625B2 (en) 2009-11-17
WO2004106376A1 (en) 2004-12-09
EP1629009A1 (de) 2006-03-01
EP1629009B1 (de) 2012-03-14
AU2004242760A1 (en) 2004-12-09
AU2004242760B2 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
BR0207068A (pt) Anticorpo monoclonal para a protéina clfa, anti-soro isolado, anticorpo isolado e anticorpo humanizado contendo o referido anticorpo, kit diagnóstico compreendendo o referido anticorpo, método para diagnóstico de uma infecção por s.aureus, composição farmacêutica para o tratamento ou prevenção da referida infecção, método para indução de de uma resposta imunológica, método para identificação de anticorpos monoclonais para a protéina clfa e fragmento ativo isolado a partir do domìnio a da protéina clfa do s.aureus
EA200801509A1 (ru) Человеческие моноклональные антитела к протеинтирозинкиназе 7 ( ptk7) и способы применения антител против ptk7
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BRPI0408317A (pt) anticorpos do receptor de igf-i para o tratamento de cáncer
BRPI0513681A (pt) composição que compreendem anticorpo her2, método, formulações farmacêuticas, polipeptìdeo, anticorpo e método de tratamento de cáncer
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EP1844077A4 (de) Dr5-antikörper und deren verwendung
EP2153848A3 (de) Monoklonale therapeutische Antikörper zur Neutralisierung von Botulin-Neurotoxinen
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
DE60321041D1 (de) Antikörper gegen krebsantigen tmeff2 und seine anwendungen
WO2023169896A8 (en) BINDING MOLECULES AGAINST FRα
WO2008079270A3 (en) Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.
ATE549355T1 (de) Zusammensetzungen die grosse und kleine gegen das selbe toxin gerichtete antikkörperfragmente enthalten
BRPI0612840A8 (pt) Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções
WO2021207948A9 (en) Anti-sars-cov-2 antibodies and uses thereof
WO2022170008A3 (en) Anti-il1rap antibodies
ECSP055849A (es) Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico
ATE402958T1 (de) Antagonisten des ige-rezeptors
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
JOP20250161A1 (ar) الأجسام المضادة لـ unc5c
EP2436774A3 (de) Therapeutische monoklonale Antikörper zur Neutralisierung von Botulinumneurotoxinen
DE602008002692D1 (de) Topische antibiotische zusammensetzung zur prävention von lyme-borreliose